managing gastrointestinal side effects of targeted therapies
DESCRIPTION
Managing Gastrointestinal Side Effects of Targeted Therapies. Amy Goodrich, MSN, NP-AC The Johns Hopkins Kimmel Cancer Center, Baltimore, MD. General Concepts of GI Toxicity in Cancer Patients. - PowerPoint PPT PresentationTRANSCRIPT
Managing Gastrointestinal Side Effects of Targeted Therapies
Amy Goodrich, MSN, NP-ACThe Johns Hopkins Kimmel Cancer
Center, Baltimore, MD
General Concepts of GI Toxicity in Cancer Patients
• Chronic GI side effects commonly cause significant morbidity and reduced quality of life in cancer patients
• GI side effects commonly overlooked due to focus on disease status
• GI symptoms can often be alleviated or eliminated
GI Toxicity in Targeted Therapies
• Spectrum of GI toxicity and causes often poorly defined
• Normal cells of the GI system, including liver, may express molecular targets
• Hepatic or GI adverse events may be alternate markers of treatment efficacy of some targeted agents
• Extensive Drug-Drug interactions• GI toxicity and management varies from single
agent to combination therapy
Diarrhea GradingGrade Description
1 Increase of > 4 stools per day over baseline; slight increase in ostomy output over baseline
2 Increase of 4-6 stools per day over baseline; moderate increase in ostomy output over baseline
3 Increase of > 7 stools per day over baselineIncontinenceRequires hospitalizationSevere increase in ostomy output over baselineLimiting self care/ADLs
4 Life-threatening; urgent intervention required
5 Death
Diarrhea
• Major cause of treatment discontinuation• Common DLT
Agent Prevalence
Sunitinib/Sorafenib 66%
Gefitinib/Erlotinib 54%
Bortezomib 51%
Bevacizumab 34%
Imatinib 33-49%
Temsirolimus 27%
Diarrhea
• EGFR overexpressed in normal GI mucosa- possibly due to increased chloride secretion leading to secretory diarrhea
• Imatinib- dose related• Bortezomib- watery diarrhea with abdominal pain and
cramps• Temsiroloimus- Immunosupressive or antimicrobial
effect could alter normal bowel flora leading to mucoid feces and colitis
• Gefitinib- Inflammatory mediators in response to cell immunity activation
Diarrhea Management
• Hydration• Electrolyte management• BRAT diet• Culture• Loperamide• Octreotide• Antibiotics if prolonged or w/neutropenia• Low dose aspirin with gefitinib
Nausea and Vomiting GradingGrade Nausea Description
1 Loss of appetite without changed in eating habits
2 Decreased oral intake without weight loss, dehydration or malnutrition
3 Inadequate caloric or fluid intake; requires tube feeding, TPN or hospitalization
Grade Vomiting Description
1 1-2 episodes at least 5 minutes apart in 24 hours
2 3-5 episodes at least 5 minutes apart in 24 hours
3 > 6 episodes at least 5 minutes apart in 24 hoursTube feeding or TPN requiredHospitalization
4 Life threatening; urgent intervention required
5 Death
Nausea and VomitingAgent Nausea Prevalence Vomiting Prevalence NCCN Emetogenic
potentialBortezomib 64% 36% Minimal
Sunitinib/Sorafenib 58% 39% Minimal to Low
Bevacizumab Not reported 52% Minimal
Imatinib 47-68% 21-49% Minimal to Low
Temsirolimus 37% 19% Not reported
Gefitinib/Erlotinib 33% 23% Minimal to Low
Nausea and Vomiting
• Cited as the most concerning symptom of antineoplastic therapy
• Significantly impacts quality of life• Affected by: specific agent, dose, schedule and
route, patient-related variables • Multifactorial • Most Targeted Therapies have low to minimal
emetogenic potential • Is it time for a revised CTCAE to reflect long term
therapy vs. traditional chemo cycles?
Management of Nausea and Vomiting
• Follow guidelines for prevention and treatment
• Hydration• Dietary changes- small frequent meals, bland
foods, full liquids, room temperature foods• Nonpharmacologic- acupuncture, guided
imagery, music therapy, progressive muscle relaxation, many others
Recommended Antiemesis ProphylaxisIV agents Oral agents
• Low- Dexamethasone pre OR Metaclopramide pre and prn OR Prochlopreazine pre and prn+/- lorazepam pre and prn+/- H2 blocker or PPI
• Minimal – No prophylaxis
• PRN antiemetics recommended
Oral Mucositis GradingGrade Description
1 No symptoms or mild symptoms; no intervention
2 Moderate pain; no change in oral intake; modified diet
3 Severe pain; interfering with oral intake
4 Life threatening; urgent intervention required
5 Death
Stomatitis/MucocitisAgent Prevalence
Sunitinib/Sorafenib 53%
Temsirolimus 41%
Bevacizumab 32%
Gefitinib/Erlotinib 17%
Oral Mucositis Management
• Oral care- Saline rinses, soft tooth brushes• Hydration• Dietary modifications- Soft diet, bland foods• Analgesics- topical and systemic• Consider anti-infectives
Dyspepsia GradingGrade Description
1 Mild symptoms; no intervention
2 Moderate symptoms; medical intervention required
3 Severe symptoms; surgical intervention required
DyspepsiaAgent Prevalence
Sunitinib/Sorafenib 46%
Bevacizumab 24%
Bortezomib 13%
Imatinib 9-19%
Dyspepsia Management
• Pharmacologic treatment, watch for drug-drug interactions
• Dietary changes- avoid spicy or fatty foods, no eating within 2 hours of bedtime
Liver Function Abnormality GradingGrade ALT/AST Description
1 Up to 3.0 x ULN
2 >3.0-5 x ULN
3 >5-20 x ULN
4 >20 x ULN
Grade Alk Phos Description1 Up to 2.5 x ULN2 >2.5-5 x ULN3 >5-20 x ULN4 >20 x ULN
Grade Bilirubin Description
1 Up to 1.5 x ULN
2 >1.5-3 x ULN
3 >3-10 x ULN
4 >10 x ULN
Liver Function Abnormalities
Agent Prevalence Dose Reductions
Sunitinib/Sorafenib
SGOT 72%SGPT 61%Bilirubin 37%
Sunitinib- Hold for Gr 3 or 4 hepatotoxicity; discontinue if no resolution (Black Box Warning)Sorafenib- Discontinue for drug induced hepatitis
Gefitinib/Erlotinib
2-4% Gefitinib- Discontinue for drug induced hepatitisErlotinib- Dose interruption and/or reduction, may require discontinuation
Imatinib Transaminases 1.1-3%Bilirubin 0.4-3.5%
Dose interruption and reduction
GI EmergenciesAgent Prevalence
Bevacizumab GI Hemorrhage 24% (Black Box Warning)Colitis 6%GI perforation/Fistula 0.9-2.4% (Black Box Warning)
Bortezomib Paralytic ileus 21%
Imatinib GI Hemorrhage 0.2-5%GI perforation rare
Gefitinib/Erlotinib GI perforation rare
Conclusions
• Targeted therapies carry high incidence of GI toxicity
• Usually mild• Patient distress easily overlooked by providers• Chronic dosing of targeted therapies makes
side effect control critical